Jeff Carroll joined the Allen Institute in 2026 and leads the team focused on translational research efforts around Huntington’s disease (HD) within the Brain Health accelerator. He received both his BSc and PhD at the University of British Columbia. After a postdoc at Harvard Medical School, Jeff began an independent research lab at Western Washington University, which later moved to the University of Washington. While a graduate student, he co-founded HDBuzz.net, a unique online information platform where HD families can get updates about cutting-edge HD science in news stories written by HD researchers in plain language.

Over his scientific career, Jeff has used mouse and cellular models with a goal of hastening the development of effective treatments for HD. The lab has had a long-term interest in “Huntington-lowering” strategies, using diverse technologies to lower levels of the mutant gene product that is the cause of every case of HD.

Jeff’s area of expertise is in HD and related repeat expansion disorders. He has carried out foundational work in the development of antisense oligonucleotides as a therapeutic option in HD, other rare expansion disorders, and nano-rare disorders. In parallel to this translational research, he has conducted work into better understanding the pathogenic mechanisms of HD, with a particular focus on understanding the origin of transcriptional dysregulation in vulnerable neurons.

‍